All News

The data highlight novel therapies and biomarkers shaping personalized cancer care.

New research highlights the benefits of early oseltamivir treatment for hospitalized patients with influenza, reducing mortality and readmission rates while optimizing care.

The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.

Obesity and type 2 diabetes in youth significantly increase the risk of osteoporosis and fractures, highlighting the need for early intervention and healthy habits.

Receiving a COVID-19 vaccination vastly reduced the risk of long-term hospitalization, necessitating dialysis, and morbidity in patients hospitalized with acute kidney injury related to SARS-CoV-2 infection.

The agent, Kirsty, represents a more affordable alternative to Novolog.

Adam James, PharmD, and Chris Altman, PharmD, discuss renewed public scrutiny of thimerosal, its limited use in vaccines today, and how new guidance may affect pharmacists and patient confidence moving forward.

The data showed patients with relapsed or refractory multiple myeloma achieved a 73% overall response rate.

Patients with chronic kidney disease (CKD) were more likely to get vaccinated for influenza and pneumococcal following a health care provider’s recommendation.

Finerenone emerges as a promising treatment for patients with diabetes and chronic kidney disease, significantly reducing cardiovascular and renal risks.

Millions of seniors and Medicare beneficiaries managing chronic conditions have new options for medication delivery and adherence support.

The fibroblast growth factor receptor 2b (FGFR2b)-inhibiting bemarituzumab demonstrated improvements in overall survival and other key secondary end points compared with placebo in first-line gastric cancer.

Dave’s Pharmacy in Alliance, Nebraska, was named the Pharmacy of the Year for cutting-edge patient care.

Independent pharmacy owners Raj Chhadua and Marc Ost are turning to AI-powered tools to streamline operations, improve efficiency, and enhance patient engagement—without sacrificing the personal touch.

Combination therapy with trastuzumab emtansine and trastuzumab significantly enhances survival rates in HER2-positive early breast cancer, outperforming trastuzumab alone.

From vaccine drives and prescriber dinners to YouTube education and automated workflows, these pharmacy owners are finding innovative, hands-on ways to expand services, boost revenue, and stay connected to the communities they serve.

The expanded instructions for use labeling expand on the Farawave and Farawave Nav Pulsed Field Ablation (PFA) catheters.

Debra Patt, MD, PhD, MBA; and Houston Holmes, MD, discuss the ramifications of the FDA's removal of REMS requirements for approved chimeric antigen receptor (CAR) T-cell (CAR T) therapies.

Arkansas' "shot heard round the pharmacy world": Preventing pharmacy benefit managers from owning pharmacies raises an interesting question for the field.

BCPPs can address behavioral health workforce shortages and advocate for expanded access and reimbursement amid evolving legislation and treatment landscapes.

This designation is significant because there are no FDA-approved treatments for transplant recipients with or preventing antibody-mediated rejection (AMR).

Pharmacy deserts challenge access to essential medications, but innovative solutions like telepharmacy and mobile units empower pharmacists to bridge the gap.

Patients with inflammatory rheumatic diseases may have a protective effect against serious COVID-19 outcomes once they receive a pneumococcal vaccination.

Laura R. Bobolts, PharmD, BCOP, shares actionable strategies for oncology pharmacists to navigate biosimilar and 505(b)(2) drug implementation, manage payer and formulary complexities, and optimize cost-effective care delivery across oncology service lines.

FDA fast-tracks TRE-515 for advanced prostate cancer, combining it with radiation therapy to enhance treatment outcomes and patient care.

Previously indicated to reduce the risk of end-stage kidney disease, cardiovascular death, and hospitalization for heart failure (HF) in chronic kidney disease, finerenone is now approved for patients with HF directly, offering a new treatment option.